fullerene c60 has been researched along with Granulocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Funakoshi-Tago, M; Mashino, T; Nakazawa, Y; Ohe, T; Sumi, K; Tago, K; Takahashi, K | 2 |
2 other study(ies) available for fullerene c60 and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
A bis-pyridinium fullerene derivative induces apoptosis through the generation of ROS in BCR-ABL-positive leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Fullerenes; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Reactive Oxygen Species | 2022 |
Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells.
Topics: Animals; Apoptosis; Fullerenes; Fusion Proteins, bcr-abl; Genes, Essential; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; Models, Biological; Mutation; Proto-Oncogene Proteins B-raf; Reactive Oxygen Species | 2022 |